More on Angiomax.
by: retireonme
Long-Term Sentiment: Strong Buy 07/20/03 06:30 pm
Msg: 1773 of 1775
Another abstract on Angiomax. I like again what other people are saying about Angiomax.
Retireonme
ncbi.nlm.nih.gov 2777673&dopt=Abstract&itool=iconabstr
Ann Thorac Surg. 2003 Jul;76(1):273-5. Related Articles, Links
Bivalrudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia.
Bott JN, Reddy K, Krick S.
Department of Cardiovascular Surgery, Orlando, Florida, USA
With advances in therapy of acute coronary syndromes, repetitive exposure to heparin has become commonplace. Consequently, the incidence of heparin-induced thrombocytopenia has risen. Limited strategies for management exist, and new thrombin inhibitors may provide safe alternatives to heparin. Two patients with documented heparin-induced thrombocytopenia underwent revascularization using a new thrombin inhibitor (Bivalrudin [Angiomax, Medicines Co, Cambridge, MA]) for anticoagulation. Both patients had uneventful perioperative hospitalizations. Thrombin inhibition with Bivalrudin (Angiomax) may provide a safe reliable alternative to heparin use in cardiac surgery.
PMID: 12842558 [PubMed - in process] |
